JP4455779B2 - Pharmaceutical composition for tumor treatment and health food - Google Patents

Pharmaceutical composition for tumor treatment and health food Download PDF

Info

Publication number
JP4455779B2
JP4455779B2 JP2001115081A JP2001115081A JP4455779B2 JP 4455779 B2 JP4455779 B2 JP 4455779B2 JP 2001115081 A JP2001115081 A JP 2001115081A JP 2001115081 A JP2001115081 A JP 2001115081A JP 4455779 B2 JP4455779 B2 JP 4455779B2
Authority
JP
Japan
Prior art keywords
shochu
pharmaceutical composition
distilled spirit
cancer
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001115081A
Other languages
Japanese (ja)
Other versions
JP2002308793A (en
Inventor
龍一 上岡
治幸 家藤
茂 廣瀬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kimigafuchi Gakuen
Original Assignee
Kimigafuchi Gakuen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kimigafuchi Gakuen filed Critical Kimigafuchi Gakuen
Priority to JP2001115081A priority Critical patent/JP4455779B2/en
Publication of JP2002308793A publication Critical patent/JP2002308793A/en
Application granted granted Critical
Publication of JP4455779B2 publication Critical patent/JP4455779B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Description

【0001】
【発明の属する技術分野】
本発明は、焼酎蒸留粕を用いることにより、腫瘍、例えば、癌、特に胃癌の予防又は治療を可能にする医薬組成物及び健康食品に関する。
【0002】
【従来の技術】
焼酎は、世界に誇れる日本国独自の蒸留酒であり、蒸留の方式が連続式であるものを焼酎甲類(ホワイトリカー)、単式であるものを焼酎乙類(本格焼酎)と呼んで区分している。両者とも、焼酎を製造するとき、蒸留終了時に蒸留釜の底部に残さが残り、これを焼酎蒸留粕(焼酎粕や蒸留廃液ともいう)と言い、本格焼酎の場合、クエン酸、蛋白質、脂肪、繊維分、微量の栄養素等を含んでいる。また、焼酎蒸留粕は、不揮発成分が濃縮されており、濾過性が非常に悪いことが特徴である(古澤淑、酒の科学、朝倉書店、1995年、60頁)。
【0003】
現在、焼酎蒸留粕の処理処分が問題となっている。ロンドン条約(廃棄物投棄による海洋汚染防止に関する条約)により、2001年から産業廃棄物の海洋投入が禁止され、これまで、一般的に行われてきた焼酎蒸留粕の海洋投入ができなくなりつつある。今後、海洋投入に替わる低コストの処理処分方法が見出せない場合、例えば九州全土だけでも、三百社を超える焼酎メーカーの大半を占める小規模メーカーが、廃業に追い込まれる懸念がある。
【0004】
以上のことから、焼酎業界では、焼酎蒸留粕の有効利用、処理法の開発が切望されており、例えば、特開平8−56584号公報には、焼酎蒸留粕から得られる飼料の製造方法が示されている。また、特開平10−130121号公報には、焼酎蒸留粕の発酵生成物からなる化粧料が示されている。特開2000−198983号公報には、酒類廃棄物を用いた多孔質炭化材の製造方法が示されている。この他、多数の焼酎蒸留粕処理に関する技術開発が、本発明の以前よりなされている。しかし、これまで焼酎蒸留粕の癌予防、治療に関わる研究は皆無であり、これを利用した医薬組成物や健康食品については、従来、全く知られていなかった。
【0005】
【発明が解決しようとする課題】
本発明の第1の目的は、焼酎蒸留粕を有効成分とする腫瘍の予防及び治療の為の医薬組成物を提供することにある。
本発明の第2の目的は、焼酎蒸留粕を有効成分とする健康食品、特に、腫瘍の予防及び治療効果を有する健康食品を提供することにある。
【0006】
【課題を解決するための手段】
本発明者らは、焼酎蒸留粕に注目し、意外にも焼酎蒸留粕が、腫瘍、例えば、癌、特に胃癌の予防・治療成分として作用することを見出し、これが従来に無い医薬組成物又は健康食品として利用できるという新たな知見を得て本発明を完成した。
即ち、本発明は、焼酎蒸留粕を有効成分として含有することを特徴とする腫瘍の予防又は治療用医薬組成物を提供する。
本発明は、又、焼酎蒸留粕を含有することを特徴とする健康食品を提供する。
【0007】
【発明の実施の形態】
本発明でいう焼酎蒸留粕とは、特に限定するものではなく、例えば芋焼酎蒸留粕、甘藷焼酎蒸留粕や麦焼酎蒸留粕というような通常のいずれの焼酎蒸留粕も使用することができる。焼酎の蒸留粕は、例えば図1に示すような焼酎の製造工程より容易に得られるものである。
具体的には、原料として、さつま芋、甘藷、麦(大麦、小麦など)、そば、米などの穀物類を蒸して砕き、これに別途調製した1次もろみを加えて2次もろみを調製し、これを常温などで醗酵させた後、蒸留し、留出分を製品である焼酎として採取し、蒸留釜の底部に溜まったものが蒸留粕、つまり焼酎蒸留粕である。尚、1次もろみは、麹に焼酎酵母と水を添加して調製した後、常温などで醗酵させたものである。
【0008】
従って、蒸留粕、つまり焼酎蒸留粕には、エタノール以外の原料に起因するさつま芋などの穀物類から由来する繊維質、たんぱく質、灰分、脂肪、一部醗酵せずに残る糖分、醗酵生成物、麹菌や酵母菌の菌体やそれらが生成したクエン酸を主体とする有機酸、アミノ酸、ビタミンなどや、醗酵中や加熱中に変性や重合又は開裂して生成した各種成分が含まれている。例えば、甘藷焼酎蒸留粕には、乾燥固形分が約5.45重量%程度含まれ、これらは、全糖約1.46重量%、直糖約0.19重量%、粗脂肪約0.21重量%、粗蛋白約1.15重量%、粗繊維約0.42重量%、有機物約5.00重量%、アルコール約0.2重量%、粗灰分約0.45重量%、Na約140ppm、K約2250ppm、Ca約220ppm、Mg約120ppm、Fe約10ppmなどが含まれており、TOCは約206000〜約237000、TNは約1700〜約23000、BODは約48900、CODは約30100である。又、その甘藷焼酎蒸留粕の遠心分離による上澄液には、乾燥固形分が約2.43〜約2.74重量%含まれ、これらは、全糖約0.77重量%、直糖約1.23重量%、粗蛋白約0.44重量%、有機物約2.27重量%、アルコール約0.2重量%、粗灰分約0.35〜約0.47重量%、Na約150ppm、K約2380ppm、Ca約6.3ppm、Mg約103ppm、Fe約3.2ppmなどが含まれており、TOCは約11100〜約11700、TNは約640〜約1000、BODは約30100、CODは約17600である(“醸造物の成分” 日本醸造協会 平成11年12月発行第139頁〜第141頁第IX章“蒸留廃液成分”の項)。又、麦焼酎蒸留粕の組成は、特開平10−229825号公報の第4頁に記載されている。
【0009】
本発明では、このような焼酎蒸留粕をそのまま用いることができるが、遠心分離による上澄液を用いるのが好ましい。遠心分離は、常法により行うことができる。
本発明では、又、焼酎蒸留粕をそのまま又はその遠心分離による上澄液を、乾燥化して用いることもできる。乾燥の方法は、通常知られるいかなる乾燥方法であって良いが、好ましくはスプレードライや凍結乾燥などの工業的に利用可能な方法が用いられる。
【0010】
本発明に用いる焼酎蒸留粕は、そのまま医薬組成物や健康食品として、或いは凍結乾燥、滅菌などの加工処理をへて医薬組成物や健康食品として提供されることにより、腫瘍などの細胞増殖性疾患の予防または治療に対して有効に働く。また従来公知の医薬組成物や健康食品に必須成分として含まれて提供されることによっても、腫瘍などの細胞増殖性疾患の予防または治療に対して有効に働く。
本発明でいう腫瘍とは、例えば急性白血病、慢性白血病、悪性リンパ腫、多発性骨髄腫、マクログロブリン血症などの造血器癌や、脳腫瘍、頭頸部癌、乳癌、肺癌、食道癌、胃癌、大腸癌、肝癌、胆嚢・胆管癌、膵癌、膵島細胞癌、腎細胞癌、副腎皮質癌、膀胱癌、前立腺癌、睾丸腫瘍、卵巣癌、子宮癌、絨毛癌、甲状腺癌、悪性カルチノイド腫瘍、皮膚癌、悪性黒色腫、骨肉腫、軟部組織肉腫、神経芽細胞腫、ウィルムス腫瘍、胎児性横紋筋肉腫、網膜芽細胞腫などの固形腫瘍を形成する腫瘍、またはそれらに由来・関連する癌疾患である。本発明の焼酎蒸留粕が、有効成分として働くことにより予防・治療できる腫瘍は、前記癌に限定されるものではないが、焼酎蒸留粕を含む医薬組成物や健康食品が経口的に使用される場合、対象となる腫瘍疾患が、胃癌であるときに予防・治療上、特に効果がある。
【0011】
本発明に用いられる焼酎蒸留粕は、それ自体公知の薬理的に許容される担体、賦形剤、崩壊剤、矯正剤、増量剤、希釈剤、溶解補助剤などと混合し、公知の方法に従って医薬組成物とすることができる。但し、焼酎蒸留粕を経口投与する場合、焼酎蒸留粕を医薬組成物全体に対して2重量%以上、好ましくは5重量%以上、特に5〜20重量%となるように配合するのがよい。
本発明の医薬組成物は、例えば錠剤、カプセル剤、顆粒剤、散剤、粉末剤、丸剤、溶剤、ドリンク剤、注射剤、点滴剤、座剤などの形態に製剤化することができる。このような製剤は経口的もしくは非経口的に投与することができる。
【0012】
本発明の医薬組成物を腫瘍の予防・治療等に使用する場合の投与量は、投与対象、投与経路、症状などによっても異なるが、通常、経口的に投与する場合、成人の場合、1日の投与量が50mg/日〜500g/日となるよう、1日1〜3回程度投与するのがよい。これにより、腫瘍、特に胃癌などに対し、顕著な予防・治療効果が得られる。
また、医薬組成物が、注射剤または点滴剤として非経口的に投与されるとき、場合によっては、適宜処理した焼酎蒸留粕を分子集合体に含有させて投与せしめることもできる。焼酎蒸留粕を含有させる分子集合体の例としては、脂肪乳剤、高分子ミセル、アルブミンなどのタンパクとの複合体、リポソームなどが挙げられるが、安全性などの点からリポソームが最も好ましものとして挙げられる。
【0013】
例えば、焼酎蒸留粕を含有するリポソーム溶液は、公知のいかなる方法によって形成してもよい。例えば薄膜法、逆相蒸発法、凍結融解法、エタノール注入法、高圧乳化法、超音波分散法、透析法、エクストルージョン法など、公知の製造方法を適宜利用することができ、更には特開平9−87168号公報に記載される方法などを利用してもよい。
このようにして得られる焼酎蒸留粕を含有するリポソーム溶液は、限外濾過、遠心分離、ゲル濾過等の方法によって精製してよく、また濃縮や希釈等の操作を自由に行ってもよく、注射剤や点滴剤として調製され医薬組成物として用いることができる。
注射剤や点滴剤のような形態で、本発明の医薬組成物を血中に投与する場合、一回量として焼酎蒸留粕を1×10−1〜1×10−6Mの濃度で含む溶液を0.01〜100ml/kg体重、好ましくは焼酎蒸留粕を5×10−2〜5×10−4Mの濃度で含む溶液を1〜50ml/kg体重で1日1〜3回程度投与するのがよい。
【0014】
本発明に用いられる焼酎蒸留粕は、それ自体公知の食品的に許容される食材、防腐剤、増粘剤、着色料、酸化防止剤、添加剤、調味料等の素材と混合し、公知の方法に従って健康食品とすることができる。本発明でいう健康食品とは、本発明における癌の予防または治療の効果を持つ焼酎蒸留粕そのものであっても良いが、好ましくは従来公知の食品または健康食品に、本発明における焼酎蒸留粕を配合してなるものである。但し、焼酎蒸留粕を摂取する場合、焼酎蒸留粕を健康食品全体に対して2重量%以上、好ましくは5重量%以上、特に5〜10重量%となるよう配合するのがよい。
【0015】
健康食品は、通常の方法により、例えば錠剤、ソフトカプセル剤、ハードカプセル剤、顆粒剤、固形剤、散剤、粉末剤、丸剤、溶剤、チュアブル剤、ドリンク剤、ドレッシング類、菓子類などの形態に製造することができる。また、これらの形態にとらわれることなく、本発明の健康食品は、広く一般の食品形態に加工・配合して提供しても良い。このような健康食品は、例えば、天ぷら、お好み焼き、たこ焼き、焼きイモ、大学イモ、加工肉、おでん、ハンバーガー、肉まん、ギョウザ、ホットドック、サンドイッチ、カレー、ハヤシライス、海苔、漬物、キムチ等の通常の食品はもちろん、お茶、コーヒー、ココア、野菜ジュース、青汁、味噌汁、スープ等の液状飲食品や、本発明における焼酎蒸留粕を添加・配合できるものであれば、うどん、焼きそば、そば、ラーメンなどの麺類や、パン、ビスケット、パスタ、マカロニ、加工米、加工豆、せんべい等の澱粉系食品、あるいはキャンデー、ガム、チョコレート、ケーキ、ショートクリーム、アイスクリーム、和菓子等の甘味菓子類、加工牛乳、ヨーグルト等の乳製品や醤油、ソース、食酢、ラー油、タバスコ、洋風ドレッシング、和風ドレッシング、青じそドレッシング、味噌、ニョクマム、マヨネーズ等の調味料などのいかなる飲食品にも用いることができる。
【0016】
焼酎蒸留粕は、各食品、飲食品の特性、目的に応じ、適当な製造工程の段階で、適宜配合すればよい。本発明の健康食品を提供する場合、かかる食品、飲食品全体に対して焼酎蒸留粕を2重量%以上、好ましくは10重量%以上配合して提供されるのが、癌の予防・治療の点から好ましい。
本発明の健康食品の形態は、これらの態様に限定されず、製造方法も限定されないが、しいて具体例を挙げるとすれば、焼酎蒸留粕を5〜30重量部(以下、部と略称する)、食用精製魚油を5〜30部、醸造酢5〜25部、果糖ぶどう糖液糖5〜15部、食塩0.5〜5部、砂糖0.2〜3部、キサンタンガム0.1〜2部、グルタミン酸ソーダ0.1〜2部、香辛料0.05〜3部、バランスとして水を20〜50部を原料として加え常法に従って混合しドレッシングとすることができる。また、焼酎蒸留粕を5〜150部、カカオマスを20〜60部、カカオバター20〜60部、砂糖70〜110部、牛乳1〜5部、ショートニング3〜20部を原料として加え常法に従ってチョコレートとすることができる。また、焼酎蒸留粕を10〜500部、小麦粉100〜600部、砂糖50〜350部、マーガリン50〜300部、全卵粉20〜100部、バニラエッセンス0.5〜8部、水70〜250部を原料として加え常法に従ってクッキーとすることができる。また焼酎蒸留粕0.1〜8部、ココアパウダー0.5〜8部、砂糖0.5〜8部、脱脂粉乳0.1〜3部、乳化剤0.05〜2部、食塩0.01〜0.5部、バニラフレーバー0.01〜0.5部、処理水70〜150部を原料として加え、常法に従ってココア飲料とすることができる。
【0017】
本発明における健康食品は、人体に対して無毒性であるから、その摂取量に特に制限はないが、実際に健康食品として摂取する場合には、成人の場合、1日の摂取量が1〜1000mg/kg体重/日となるよう、1日1〜3回程度摂取するのがよい。これにより、癌、特に胃癌などに対し、顕著な予防・治療効果が得られる。
【発明の効果】
本発明の焼酎蒸留粕を有効成分とする医薬組成物および健康食品は、副作用もなく、安全であり、腫瘍、特に胃癌の予防または治療に極めて有効である。
【0018】
【実施例】
以下に実施例及び参考例に基づいて本発明をさらに具体的に説明するが、本発明はこれらに限定されるものではない。
実施例1
<芋焼酎蒸留粕による腫瘍細胞の増殖抑制試験>
1−1.芋焼酎蒸留粕凍結乾燥物質の調製
国税庁醸造研究所環境保全研究室、家藤治幸博士より入手した芋焼酎蒸留粕25.92gを遠心分離し、上澄み液を凍結乾燥して、0.889gの芋焼酎蒸留粕凍結乾燥物質を得た。得られた凍結乾燥物質の赤外線吸収スペクトルと上澄み液の紫外線吸収スペクトルとをそれぞれ図2及び3に示す。
【0019】
1−2.使用細胞・培養培地の説明
ヒト肺腺がん細胞(RERF−LC−OK)は、国立衛生試験所より購入したものを用いた。ヒト胃がん細胞(GT3TKB)およびヒト肝臓がん細胞(Hep−G2)は、理化学研究所・細胞開発銀行より購入したものを用いた。マウス由来悪性黒色腫細胞(B16−melanoma)は、大日本製薬より購入したものを用いた。培養培地としては、ヒト肺腺がん細胞(RERF−LC−OK)には、RPMI−1640(+10%FBS)を、ヒト胃がん細胞(GT3TKB)、ヒト肝臓がん細胞(Hep−G2)およびマウス由来悪性黒色腫細胞(B16−melanoma)には、DME−M(+10%FBS)を培養培地として使用し、増殖抑制試験に用いた。
【0020】
1−3.試験サンプル作成
1−1で調製した芋焼酎蒸留粕凍結乾燥物質を29倍量(凍結乾燥前の原液の体積に相当)のPBS(−)[ここでPBSはリン酸緩衝液である]に溶解させた。濃度は34.5mg/mlであった。溶解後、得られた液を孔径0.45μmのフィルターで濾過滅菌処理し、試験サンプルを得た。
【0021】
1−4.増殖抑制試験
増殖抑制試験は、酵素活性測定法であるWST−1 assay法により行った。テトラゾリウム塩WST−1を用いたWST−1 assay法は、細胞のWST−1代謝物による発色によって細胞増殖活性を測定する方法である。原理は、WST−1が細胞内ミトコンドリアの脱水素酵素のよい基質であり、生存能の高い細胞ほど分解されるWST−1量が多く、その結果生じるホルマザン量が生存細胞数とよく対応することに基づいている。
1−2に示した各細胞について、初期細胞数を1.0×104Cells/mlに調製した細胞懸濁液100μl/wellを、96wellマルチプレートに播種し、24時間プレインキュベーション後に、1−3で得た試験サンプルを10μl/well添加した。37℃、CO2濃度5%、湿度95%の条件下で48時間または72時間培養後、WST−1溶液を10μl/well添加した。更に3時間培養後、分光光度計(Molecular Device)を用いて、450nmの吸光度を測定した。細胞増殖抑制効果は、陰性対照としてPBS(−)を添加した場合の吸光度(AControl)および試験サンプルを添加した場合の吸光度(AMean)の比(AMean/AControl)を算出し、評価を行った。
【0022】
1−5.結果
芋焼酎蒸留粕凍結乾燥物質の種々の腫瘍細胞に対する細胞増殖抑制効果の検討を行った。結果を図4及び表1に示した。
【0023】
【表1】

Figure 0004455779
【0024】
試験サンプル添加48時間後では、ヒト肝臓がん細胞(Hep−G2)に対する増殖抑制効果は、ほとんど見られなかったものの、マウス由来悪性黒色腫細胞(B16−melanoma)および、ヒト肺腺がん細胞(RERF−LC−OK)に対しては約70%、ヒト胃がん細胞(GT3TKB)に対しては約80%、細胞の増殖を抑制していることが観測された。試験サンプル添加72時間後では、ヒト肝臓がん細胞(Hep−G2)に対しても、やや増殖抑制効果が見られ、更にマウス由来悪性黒色腫細胞(B16−melanoma)および、ヒト肺腺がん細胞(RERF−LC−OK)では約60%、細胞の増殖を抑制し、ヒト胃がん細胞(GT3TKB)に対しては約90%もの高い増殖抑制効果が見られた。
【0025】
実施例2
<麦焼酎蒸留粕による腫瘍細胞の増殖抑制試験>
2−1.麦焼酎蒸留粕凍結乾燥物質の調製
国税庁醸造研究所環境保全研究室、家藤治幸博士より入手した麦焼酎蒸留粕26.65gを遠心分離し、上澄み液を凍結乾燥して、3.518gの麦焼酎蒸留粕凍結乾燥物質を得た。得られた凍結乾燥物質の赤外線吸収スペクトルと上澄み液の紫外線吸収スペクトルとをそれぞれ図5及び6に示す。
【0026】
2−2.使用細胞・培養培地の説明
使用細胞、使用培地については、実施例1−2で用いたものと同様のものを用いた。
【0027】
2−3.試験サンプル作成
2−1で調製した麦焼酎蒸留粕凍結乾燥物質を6.5倍量(凍結乾燥前の原液の体積に相当)のPBS(−)に溶解させた。濃度は150mg/mlであった。溶解後、得られた液を孔径0.45μmのフィルターで濾過滅菌処理し、試験サンプルを得た。
【0028】
2−4.増殖抑制試験
増殖抑制試験については、細胞として2−2に示した各細胞を用い、試験サンプルとして1−3に示した試験サンプルの替わりに、2−3で示した試験サンプルを用いた以外は、実施例1の1−4に示した増殖抑制試験と同様に行った。
【0029】
2−5.結果
麦焼酎蒸留粕凍結乾燥物質の種々の腫瘍細胞に対する細胞増殖抑制効果の検討を行った。結果を図7及び表2に示した。
【0030】
【表2】
Figure 0004455779
【0031】
図7から明らかなように、用いた全ての腫瘍細胞に対し、90%以上の顕著な細胞増殖抑制効果が見られた。
実施例3
<米焼酎蒸留粕による腫瘍細胞の増殖抑制試験>
3−1.米焼酎蒸留粕凍結乾燥物質の調製
国税庁醸造研究所環境保全研究室、家藤治幸博士より入手した米焼酎蒸留粕25.67gを遠心分離し、上澄み液を凍結乾燥して、0.86gの米焼酎蒸留粕凍結乾燥物質を得た。得られた凍結乾燥物質の赤外線吸収スペクトルと上澄み液の紫外線吸収スペクトルとをそれぞれ図8及び9に示す。
【0032】
3−2.使用細胞・培養培地の説明
ヒト肺腺がん細胞(RERF−LC−OK)は、国立衛生試験所より購入したものを用いた。ヒト胃がん細胞(GT3TKB)、およびヒト肝臓がん細胞(Hep−G2)は、理化学研究所・細胞開発銀行より購入したものを用いた。使用培地については、実施例1−2で用いたものと同様のものを用いた。
【0033】
3−3.試験サンプル作成
3−1で調製した米焼酎蒸留粕凍結乾燥物質を28.7倍量(凍結乾燥前の原液の体積に相当)のPBS(−)に溶解させた。濃度は34.7mg/mlであった。溶解後、得られた液を孔径0.45μmのフィルターで濾過滅菌処理し、試験サンプルを得た。
【0034】
3−4.増殖抑制試験
増殖抑制試験については、細胞として3−2に示した各細胞を用い、試験サンプルとして1−3に示した試験サンプルの替わりに、3−3で示した試験サンプルを用いた以外は、実施例1の1−4に示した増殖抑制試験と同様に行った。
【0035】
3−5.結果
米焼酎蒸留粕凍結乾燥物質の種々の腫瘍細胞に対する細胞増殖抑制効果の検討を行った。結果を図10及び表3に示した。
【0036】
【表3】
Figure 0004455779
【0037】
図10から明らかなように、ヒト胃がん細胞およびヒト肺腺がん細胞に対し、90%以上の顕著な細胞増殖抑制効果が見られた。
これらの結果より芋焼酎蒸留粕や麦焼酎蒸留粕などの焼酎蒸留粕には、癌の治療、予防効果があることが示唆された。
【0038】
参考例
<焼酎蒸留粕の正常ラットに対する単回投与毒性試験>
本発明に用いる焼酎蒸留粕の食品および医薬品としての安全性を確認するため、正常ラットを用いて毒性試験を行ったので、参考例として、以下に、毒性の試験検体作成、試験方法及びその結果を示す。
(試験検体作成)
芋焼酎蒸留粕凍結乾燥物質は29倍量のPBS(−)、麦焼酎蒸留粕凍結乾燥物質は、6.5倍量のPBS(−)に溶解(原液濃度に相当)した。濃度は、芋焼酎蒸留粕凍結乾燥物質が34.5mg/ml、麦焼酎蒸留粕凍結乾燥物質が150mg/mlである。溶解後、0.45μmフィルターで濾過滅菌処理したものを使用した。
【0039】
(試験方法)
動物実験は九動株式会社の施設で行った。
正常ラットを無作為に1群4匹ずつに群分け、焼酎蒸留粕の単回投与毒性試験を行った。投与法は、経口投与および静脈注射とした。投与量は15ml/kgとし、経口および尾静脈から全量を約3分間で投与した。実験期間中は一般状態観察および体重測定を投与開始後から毎日行った。投与6日後には、全例について約19時間の絶食を行った後、エーテル麻酔下で切開後、腹部大静脈から採血し、採取した血液を室温で約60分間放置後、3000回転/分で15分間遠心分離し、得られた血清を用いて生化学自動分析装置(富士ドライケム3500V、富士フィルム株式会社製)により、アルブミン、ALP活性、尿素窒素、クレアチニン、ブドウ糖、GOT/AST活性、GPT/ALT活性、総ビリルビン酸、総コレステロール、中性脂肪、総タンパク質を測定した。
全ての動物について採血を行った後、解剖をして諸器官の肉眼的観察を行った。剖検後、肝臓、胸腺、心臓、腎臓、肺、脾臓を摘出し、器官重量を測定するとともに、当日の体重を基に体重比臓器重量を算出した。
【0040】
尚、本実験に使用した代表的器具を参考のために以下に記す。
1.生化学自動分析装置 富士ドライケム3500V (商品名、富士フィルム株式会社製)
Nicipet Ex(1000μ) (商品名、ニチリョウ)
富士ドライケムクリーンチップ (商品名、富士フィルム株式会社製)
富士ドライケムスライド ALB−P (商品名、富士フィルム株式会社製)
富士ドライケムスライド ALP−P (商品名、富士フィルム株式会社製)
富士ドライケムスライド BUN−P (商品名、富士フィルム株式会社製)
富士ドライケムスライド CRE−P (商品名、富士フィルム株式会社製)
富士ドライケムスライド GLU−P (商品名、富士フィルム株式会社製)
富士ドライケムスライド GOT/AST−P (商品名、富士フィルム株式会社製)
富士ドライケムスライド GPT/ALT−P (商品名、富士フィルム株式会社製)
富士ドライケムスライド TBIL−P (商品名、富士フィルム株式会社製)
富士ドライケムスライド TCHO−P (商品名、富士フィルム株式会社製)
富士ドライケムスライド TG−P (商品名、富士フィルム株式会社製)
14. 富士ドライケムスライド TP−P (商品名、富士フィルム株式会社製)
【0041】
(結果)
焼酎蒸留粕凍結乾燥物質の正常ラットに対する単回投与毒性試験について検討した。試料濃度は、原液相当濃度に設定した。投与直後から一週間にわたり、ラットの一般状態を観察した結果、いずれの投与群においても異常症状および死亡例は見られず、また、体重測定(図11)からも、コントロール群とサンプル投与群との間に有意差は見られなかった。さらに、解剖後の肉眼的観察からは、全ての器官において異常所見は見られなかった。また、剖検後、心臓、胸腺、腎臓、肝臓、脾臓、肺を摘出し、臓器重量を測定し、当日の体重を基に体重比臓器重量(ラットの体重100g当たりの臓器重量)を算出した。結果を図12、図13に示す。図から明らかなように、コントロール群と投与群との間に体重比臓器重量の有意差は観察されなかった。ここで注目すべきは、静脈投与した場合の最初の標的臓器となるために、傷害頻度が高いといわれる腎臓、および経口投与した場合に薬物の傷害を受けやすい肝臓に、投与による影響が見られなかったことである。
次に、採血した血液を遠心分離して得られた血清を用いて、生化学検査を行った。結果を図14〜17に示す。図から明らかなように、全ての検査項目においてコントロール群とサンプル投与群との間に有意差は見られなかった。
【0042】
以上の結果から、麦および芋焼酎蒸留粕は、▲1▼正常ラットに対して急性有害作用および致死毒性を示さないことが明らかになった。▲2▼特定の臓器に対する毒性を示さないことが明らかになった。▲3▼生化学検査において異常を示さないことが明らかになった。よって、本発明の焼酎蒸留粕は、医薬組成物としても、健康食品としても安全に使用できることが示唆された。
【図面の簡単な説明】
【図1】 焼酎の製造工程を示す図である。
【図2】 芋焼酎蒸留粕の上澄み液の凍結乾燥物質の赤外線吸収スペクトルを示す。
【図3】 芋焼酎蒸留粕の上澄み液の紫外線吸収スペクトルを示す。
【図4】 芋焼酎蒸留粕の種々の腫瘍細胞に対する増殖抑制効果を示す図である。
【図5】 麦焼酎蒸留粕の上澄み液の凍結乾燥物質の赤外線吸収スペクトルを示す。
【図6】 麦焼酎蒸留粕の上澄み液の紫外線吸収スペクトルを示す。
【図7】 麦焼酎蒸留粕の種々の腫瘍細胞に対する増殖抑制効果を示す図である。
【図8】 米焼酎蒸留粕の上澄み液の凍結乾燥物質の赤外線吸収スペクトルを示す。
【図9】 米焼酎蒸留粕の上澄み液の紫外線吸収スペクトルを示す。
【図10】 米焼酎蒸留粕の種々の腫瘍細胞に対する増殖抑制効果を示す図である。
【図11】 ラットの体重変化を示す図である。
【図12】 経口投与後のラットの各臓器重量を示す図である。
【図13】 静脈投与後のラットの各臓器重量を示す図である。
【図14】 経口投与ラットの血液生化学的検査の各結果を示す図である。
【図15】 経口投与ラットの血液生化学的検査の各結果を示す図である。
【図16】 静脈投与ラットの血液生化学的検査の各結果を示す図である。
【図17】 静脈投与ラットの血液生化学的検査の各結果を示す図である。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a pharmaceutical composition and a health food that enable prevention or treatment of tumors, for example, cancer, particularly gastric cancer, by using shochu distillers.
[0002]
[Prior art]
Shochu is a distilled liquor unique to Japan that is proud of the world. Those that use a continuous distillation method are called shochu shellfish (white liquor), and those that use a single method are called shochu oysters (real shochu). Yes. In both cases, when producing shochu, a residue remains at the bottom of the distillation kettle at the end of distillation. This is called shochu distilled spirit (also called shochu or distilled waste liquid). In the case of authentic shochu, citric acid, protein, fat, Contains fiber and trace amounts of nutrients. Shochu distillery is characterized by its concentration of non-volatile components and very poor filterability (Furusawa Kaoru, Sake no Kagaku, Asakura Shoten, 1995, p. 60).
[0003]
At present, disposal of shochu distillery is a problem. The London Convention (Convention on the Prevention of Marine Pollution by Waste Disposal) has banned the introduction of industrial waste into the ocean since 2001. In the future, if a low-cost treatment / disposal method that replaces ocean input cannot be found, for example, even in the whole of Kyushu, there is a concern that small-scale manufacturers, which account for the majority of over 300 shochu manufacturers, will be forced out of business.
[0004]
From the above, in the shochu industry, effective utilization of shochu distillers and development of treatment methods are eagerly desired. For example, Japanese Patent Application Laid-Open No. 8-56584 discloses a method for producing feed obtained from shochu distillers. Has been. JP-A-10-130121 discloses a cosmetic comprising a fermentation product of shochu distiller. Japanese Unexamined Patent Publication No. 2000-198983 discloses a method for producing a porous carbonized material using liquor waste. In addition, many technical developments related to the treatment of shochu distillers have been made before the present invention. However, there has been no research related to cancer prevention and treatment of shochu distilled spirits so far, and pharmaceutical compositions and health foods using this have not been known at all.
[0005]
[Problems to be solved by the invention]
The first object of the present invention is to provide a pharmaceutical composition for the prevention and treatment of tumors containing shochu distilled spirit as an active ingredient.
The second object of the present invention is to provide a health food containing a shochu distilled spirit as an active ingredient, particularly a health food having a preventive and therapeutic effect on tumors.
[0006]
[Means for Solving the Problems]
The present inventors have focused on shochu-distilled rice cake, and surprisingly found that shochu-distilled rice cake acts as a preventive / therapeutic component for tumors, for example, cancer, particularly gastric cancer, and this is an unprecedented pharmaceutical composition or health. The present invention was completed by obtaining new knowledge that it can be used as food.
That is, the present invention provides a pharmaceutical composition for preventing or treating tumors, comprising a shochu distilled spirit as an active ingredient.
The present invention also provides a health food characterized by containing a shochu distiller.
[0007]
DETAILED DESCRIPTION OF THE INVENTION
The shochu distiller referred to in the present invention is not particularly limited, and any ordinary shochu distiller such as a shochu shochu distiller, a sweet potato shochu distiller or a wheat shochu distiller can be used. The shochu liquor is easily obtained from the manufacturing process of shochu as shown in FIG.
Specifically, as a raw material, steamed and crushed grains such as sweet potato, sweet potato, wheat (barley, wheat etc.), buckwheat, rice, etc., and separately prepared primary mash to prepare secondary mash, This is fermented at room temperature and then distilled, and the distillate is collected as a product shochu, and what is collected at the bottom of the still is a distiller, that is, a shochu distiller. The primary moromi is prepared by adding shochu yeast and water to koji, followed by fermentation at room temperature.
[0008]
Therefore, distilled spirits, that is, shochu distilled spirits, include fiber, protein, ash, fat, sugar remaining from fermentation without fermentation, fermentation products, koji molds, etc., derived from raw materials other than ethanol. And organic acids mainly composed of citric acid produced by them, amino acids, vitamins, and various components produced by modification, polymerization, or cleavage during fermentation or heating. For example, a sweet potato shochu distilled spirit contains about 5.45% by weight of dry solids, which are about 1.46% by weight of total sugar, about 0.19% by weight of straight sugar, and about 0.21 of crude fat. Wt%, crude protein about 1.15 wt%, crude fiber about 0.42 wt%, organic matter about 5.00 wt%, alcohol about 0.2 wt%, crude ash content about 0.45 wt%, Na about 140 ppm, K includes about 2250 ppm, Ca about 220 ppm, Mg about 120 ppm, Fe about 10 ppm, TOC is about 206000 to about 237000, TN is about 1700 to about 23000, BOD is about 48900, and COD is about 30100. In addition, the supernatant obtained by centrifuging the sweet potato shochu distilled spirit contains about 2.43 to about 2.74% by weight of dry solids, which are about 0.77% by weight of total sugar and about 0.8% of straight sugar. 1.23 wt%, crude protein about 0.44 wt%, organic matter about 2.27 wt%, alcohol about 0.2 wt%, crude ash content about 0.35 to about 0.47 wt%, Na about 150 ppm, K About 2380 ppm, Ca about 6.3 ppm, Mg about 103 ppm, Fe about 3.2 ppm, etc. are contained, TOC is about 11100 to about 11700, TN is about 640 to about 1000, BOD is about 30100, COD is about 17600. (Ingredients of “Brewed Products”, Japan Brewing Association, published in December 1999, pages 139 to 141, Chapter IX “Distilled Waste Liquid Components”). The composition of the barley shochu distiller is described on page 4 of JP-A-10-229825.
[0009]
In the present invention, such a shochu distiller can be used as it is, but it is preferable to use a supernatant obtained by centrifugation. Centrifugation can be performed by a conventional method.
In the present invention, the shochu distiller can be used as it is or by centrifuging the supernatant. The drying method may be any commonly known drying method, but an industrially available method such as spray drying or freeze drying is preferably used.
[0010]
The shochu distilled spirit used in the present invention is used as it is as a pharmaceutical composition or health food, or as a pharmaceutical composition or health food after being subjected to processing such as lyophilization or sterilization, so that cell proliferative diseases such as tumors. It works effectively for prevention or treatment. In addition, it is also effective for the prevention or treatment of cell proliferative diseases such as tumors by being provided as an essential component in conventionally known pharmaceutical compositions and health foods.
The tumor in the present invention refers to hematopoietic cancer such as acute leukemia, chronic leukemia, malignant lymphoma, multiple myeloma, macroglobulinemia, brain tumor, head and neck cancer, breast cancer, lung cancer, esophageal cancer, stomach cancer, colon Cancer, liver cancer, gallbladder / bile duct cancer, pancreatic cancer, islet cell cancer, renal cell cancer, adrenal cortex cancer, bladder cancer, prostate cancer, testicular tumor, ovarian cancer, uterine cancer, choriocarcinoma, thyroid cancer, malignant carcinoid tumor, skin cancer , Malignant melanoma, osteosarcoma, soft tissue sarcoma, neuroblastoma, Wilms tumor, fetal rhabdomyosarcoma, tumors that form solid tumors such as retinoblastoma, or cancer diseases derived or related to them is there. The tumor that can be prevented and treated by the action of the shochu distilled spirit of the present invention as an active ingredient is not limited to the above cancer, but a pharmaceutical composition or health food containing the shochu distilled spirit is used orally. In particular, it is particularly effective for prevention and treatment when the target tumor disease is gastric cancer.
[0011]
The shochu distiller used in the present invention is mixed with a pharmacologically acceptable carrier, excipient, disintegrant, corrective agent, extender, diluent, solubilizing agent, etc. known per se, and according to a known method. It can be set as a pharmaceutical composition. However, when orally administering shochu distilled spirits, the shochu distilled spirit should be blended so as to be 2% by weight or more, preferably 5% by weight or more, particularly 5 to 20% by weight, based on the whole pharmaceutical composition.
The pharmaceutical composition of the present invention can be formulated in the form of tablets, capsules, granules, powders, powders, pills, solvents, drinks, injections, drops, suppositories, and the like. Such preparations can be administered orally or parenterally.
[0012]
The dosage when the pharmaceutical composition of the present invention is used for prevention / treatment of tumors and the like varies depending on the administration subject, administration route, symptom, etc., but usually when administered orally, for adults, one day It is better to administer about 1 to 3 times a day so that the dose of 50 mg / day to 500 g / day. Thereby, a remarkable preventive / therapeutic effect can be obtained for tumors, particularly gastric cancer.
Moreover, when a pharmaceutical composition is administered parenterally as an injection or an infusion, depending on the case, an appropriately treated shochu distiller can be contained in a molecular assembly for administration. Examples of molecular aggregates containing shochu distilled spirit include fat emulsions, polymer micelles, complexes with proteins such as albumin, liposomes, etc. Liposomes are the most preferred from the standpoint of safety. Can be mentioned.
[0013]
For example, a liposome solution containing shochu distiller may be formed by any known method. For example, known production methods such as a thin film method, reverse phase evaporation method, freeze-thaw method, ethanol injection method, high-pressure emulsification method, ultrasonic dispersion method, dialysis method, and extrusion method can be used as appropriate. You may utilize the method etc. which are described in 9-87168 gazette.
The liposome solution containing the shochu distiller thus obtained may be purified by methods such as ultrafiltration, centrifugation, gel filtration, etc., and operations such as concentration and dilution may be performed freely. It can be prepared as an agent or an instillation and used as a pharmaceutical composition.
When the pharmaceutical composition of the present invention is administered into blood in the form of an injection or infusion, a solution containing shochu distilled spirit at a concentration of 1 × 10-1 to 1 × 10-6M as a single dose. A solution containing 0.01 to 100 ml / kg body weight, preferably a shochu distilled spirit at a concentration of 5 × 10 −2 to 5 × 10 −4 M, is administered at 1 to 50 ml / kg body weight about 1 to 3 times a day. Good.
[0014]
The shochu distiller used in the present invention is mixed with known food-acceptable foodstuffs, preservatives, thickeners, colorants, antioxidants, additives, seasonings, etc. It can be a health food according to the method. The health food referred to in the present invention may be the shochu distilled spirit itself having the effect of preventing or treating cancer in the present invention, but preferably the conventionally known food or health food is the shochu distilled spirit in the present invention. It is a blended product. However, when ingesting shochu distilled spirits, the shochu distilled spirits should be blended so as to be 2% by weight or more, preferably 5% by weight or more, particularly 5 to 10% by weight based on the whole health food.
[0015]
Health foods are produced by conventional methods, for example, in the form of tablets, soft capsules, hard capsules, granules, solids, powders, pills, solvents, chewables, drinks, dressings, confectionery, etc. can do. Moreover, without being limited to these forms, the health food of the present invention may be provided by being processed and blended into a wide variety of general food forms. Such health foods are, for example, ordinary foods such as tempura, okonomiyaki, takoyaki, grilled potato, university potato, processed meat, oden, hamburger, meat bun, gyoza, hot dog, sandwich, curry, coconut rice, seaweed, pickles and kimchi. Of course, liquid foods and beverages such as tea, coffee, cocoa, vegetable juice, green juice, miso soup, soup, and shochu distilled spirits in the present invention can be added and blended, such as udon, yakisoba, soba, ramen, etc. Noodles, starch-based foods such as bread, biscuits, pasta, macaroni, processed rice, processed beans, and rice crackers, or sweet candy such as candy, gum, chocolate, cake, short cream, ice cream, Japanese confectionery, processed milk, yogurt Dairy products such as soy sauce, sauce, vinegar, chili oil, tabasco, Western dressing Japanese dressing, Perilla dressing, miso, can be used Nyokumamu, in any food products such as seasonings mayonnaise.
[0016]
The shochu distilled spirit may be appropriately blended at the stage of an appropriate production process according to the characteristics and purpose of each food and food. When providing the health food of the present invention, it is provided with 2% by weight or more, preferably 10% by weight or more of shochu-distilled rice, based on the whole food and food product. To preferred.
The form of the health food of the present invention is not limited to these embodiments, and the manufacturing method is not limited. However, if a specific example is given, 5 to 30 parts by weight of shochu distilled spirit (hereinafter abbreviated as “part”). ), 5-30 parts of edible refined fish oil, 5-25 parts of brewed vinegar, 5-15 parts of fructose glucose liquid sugar, 0.5-5 parts of salt, 0.2-3 parts of sugar, 0.1-2 parts of xanthan gum Sodium glutamate 0.1 to 2 parts, spices 0.05 to 3 parts, 20 to 50 parts of water as a raw material as a balance, and mixing according to a conventional method can be made into a dressing. Also, add 5 to 150 parts of shochu distilled spirit, 20 to 60 parts of cacao mass, 20 to 60 parts of cacao butter, 70 to 110 parts of sugar, 1 to 5 parts of milk and 3 to 20 parts of shortening as raw materials and add chocolate according to conventional methods. It can be. Moreover, 10-500 parts of shochu distilled spirit, 100-600 parts of flour, 50-350 parts of sugar, 50-300 parts of margarine, 20-100 parts of whole egg powder, 0.5-8 parts of vanilla essence, 70-250 water Part can be added as a raw material to make a cookie according to a conventional method. Moreover, 0.1-8 parts of shochu distilled spirits, 0.5-8 parts of cocoa powder, 0.5-8 parts of sugar, 0.1-3 parts of skim milk powder, 0.05-2 parts of emulsifier, 0.01- 0.5 parts, 0.01 to 0.5 parts of vanilla flavor and 70 to 150 parts of treated water can be added as raw materials to make a cocoa beverage according to a conventional method.
[0017]
Since the health food in the present invention is non-toxic to the human body, there is no particular limitation on the amount of intake thereof. However, when actually ingesting as a health food, the daily intake for adults is 1 to 1. It is better to take about 1 to 3 times a day so that it becomes 1000 mg / kg body weight / day. Thereby, a remarkable preventive / therapeutic effect can be obtained for cancer, particularly gastric cancer.
【The invention's effect】
The pharmaceutical composition and health food containing the shochu-distilled rice cake of the present invention as an active ingredient are safe and have no side effects, and are extremely effective for the prevention or treatment of tumors, particularly gastric cancer.
[0018]
【Example】
Hereinafter, the present invention will be described more specifically based on Examples and Reference Examples, but the present invention is not limited thereto.
Example 1
<Tumor cell growth inhibition test with potato shochu distilled spirit>
1-1. Preparation of potato shochu distilled spirit freeze-dried material
Centrifugation of 25.92g of shochu shochu distilled spirit obtained from Dr. Haruyuki Ito, Environmental Conservation Laboratory, National Tax Agency, and freeze-dried the supernatant liquid to obtain 0.889g of freeze-dried shochu shochu distilled spirit . The infrared absorption spectrum of the obtained lyophilized material and the ultraviolet absorption spectrum of the supernatant are shown in FIGS. 2 and 3, respectively.
[0019]
1-2. Explanation of cells and culture medium used
Human lung adenocarcinoma cells (RERF-LC-OK) purchased from the National Institutes of Health were used. Human gastric cancer cells (GT3TKB) and human liver cancer cells (Hep-G2) purchased from RIKEN / Cell Development Bank were used. As mouse-derived malignant melanoma cells (B16-melanoma), those purchased from Dainippon Pharmaceutical were used. As culture media, human lung adenocarcinoma cells (RERF-LC-OK) include RPMI-1640 (+ 10% FBS), human gastric cancer cells (GT3TKB), human liver cancer cells (Hep-G2) and mice. For the derived malignant melanoma cells (B16-melanoma), DME-M (+ 10% FBS) was used as a culture medium and used for the growth inhibition test.
[0020]
1-3. Test sample creation
The shochu shochu-distilled lyophilized material prepared in 1-1 was dissolved in 29 times (corresponding to the volume of the undiluted solution before lyophilization) PBS (-) [where PBS is a phosphate buffer]. The concentration was 34.5 mg / ml. After dissolution, the obtained liquid was filtered and sterilized with a filter having a pore size of 0.45 μm to obtain a test sample.
[0021]
1-4. Growth inhibition test
The growth inhibition test was performed by the WST-1 assay method, which is an enzyme activity measurement method. The WST-1 assay method using tetrazolium salt WST-1 is a method for measuring cell proliferation activity by color development of cells by WST-1 metabolites. The principle is that WST-1 is a good substrate for intracellular mitochondrial dehydrogenase, and the more viable cells, the more WST-1 is degraded, and the resulting amount of formazan corresponds well to the number of viable cells. Based on.
For each cell shown in 1-2, the initial cell number is 1.0 × 10 Four A cell suspension of 100 μl / well prepared in Cells / ml was seeded on a 96-well multiplate, and after 24 hours of pre-incubation, 10 μl / well of the test sample obtained in 1-3 was added. 37 ° C, CO 2 After culturing for 48 hours or 72 hours under the conditions of 5% concentration and 95% humidity, 10 μl / well of WST-1 solution was added. After further incubation for 3 hours, the absorbance at 450 nm was measured using a spectrophotometer (Molecular Device). The cell growth inhibitory effect was measured by the absorbance (A) when PBS (-) was added as a negative control. Control ) And the absorbance when the test sample is added (A Mean ) Ratio (A Mean / A Control ) Was calculated and evaluated.
[0022]
1-5. result
The cell growth inhibitory effect on various tumor cells of potato shochu distilled spirit lyophilized substance was examined. The results are shown in FIG.
[0023]
[Table 1]
Figure 0004455779
[0024]
48 hours after the addition of the test sample, although the growth inhibitory effect on human liver cancer cells (Hep-G2) was hardly observed, mouse-derived malignant melanoma cells (B16-melanoma) and human lung adenocarcinoma cells It was observed that cell proliferation was suppressed by about 70% for (RERF-LC-OK) and about 80% for human gastric cancer cells (GT3TKB). 72 hours after the addition of the test sample, a slight growth-inhibiting effect was also observed against human liver cancer cells (Hep-G2), and further, mouse-derived malignant melanoma cells (B16-melanoma) and human lung adenocarcinoma Cells (RERF-LC-OK) suppressed cell growth by about 60%, and human gastric cancer cells (GT3TKB) had a high growth suppression effect of about 90%.
[0025]
Example 2
<Tumor cell growth inhibition test using wheat shochu distilled spirit>
2-1. Preparation of wheat shochu distilled spirit freeze-dried material
Centrifugation of 26.65g of barley shochu distilled spirit obtained from Dr. Haruyuki Ito, Environmental Conservation Laboratory, National Tax Agency, and freeze-dried the supernatant liquid to obtain 3.518g of barley shochu distilled spirit freeze-dried material . The infrared absorption spectrum of the resulting lyophilized material and the ultraviolet absorption spectrum of the supernatant are shown in FIGS. 5 and 6, respectively.
[0026]
2-2. Explanation of cells and culture medium used
About the use cell and the use culture medium, the thing similar to what was used in Example 1-2 was used.
[0027]
2-3. Test sample creation
The barley shochu distilled spirit freeze-dried material prepared in 2-1 was dissolved in 6.5 times (corresponding to the volume of the undiluted solution before freeze-drying) PBS (-). The concentration was 150 mg / ml. After dissolution, the obtained liquid was filtered and sterilized with a filter having a pore size of 0.45 μm to obtain a test sample.
[0028]
2-4. Growth inhibition test
For the growth inhibition test, Examples were used except that each cell shown in 2-2 was used as a cell and the test sample shown in 2-3 was used instead of the test sample shown in 1-3 as a test sample. 1 was performed in the same manner as the growth inhibition test shown in 1-4 of 1-4.
[0029]
2-5. result
The cell growth inhibitory effect of the barley shochu distilled spirit freeze-dried substance on various tumor cells was examined. The results are shown in FIG.
[0030]
[Table 2]
Figure 0004455779
[0031]
As is clear from FIG. 7, a remarkable cell growth inhibitory effect of 90% or more was observed for all the tumor cells used.
Example 3
<Tumor cell growth inhibition test with rice shochu distilled spirit>
3-1. Preparation of rice shochu distiller freeze-dried material
Centrifugation of 25.67g of rice shochu distilled spirit obtained from Dr. Haruyuki Ito, Environmental Conservation Laboratory, National Tax Agency Brewing Institute, and freeze-dried the supernatant liquid to obtain 0.86g of rice shochu distilled spirit freeze-dried material . The infrared absorption spectrum of the obtained lyophilized material and the ultraviolet absorption spectrum of the supernatant are shown in FIGS. 8 and 9, respectively.
[0032]
3-2. Explanation of cells and culture medium used
Human lung adenocarcinoma cells (RERF-LC-OK) purchased from the National Institutes of Health were used. Human gastric cancer cells (GT3TKB) and human liver cancer cells (Hep-G2) purchased from RIKEN / Cell Development Bank were used. About the culture medium used, the thing similar to what was used in Example 1-2 was used.
[0033]
3-3. Test sample creation
The rice shochu-distilled rice bran freeze-dried material prepared in 3-1 was dissolved in 28.7 times PBS (corresponding to the volume of the undiluted solution before lyophilization) PBS (-). The concentration was 34.7 mg / ml. After dissolution, the obtained liquid was filtered and sterilized with a filter having a pore size of 0.45 μm to obtain a test sample.
[0034]
3-4. Growth inhibition test
For the growth inhibition test, Examples were used except that each cell shown in 3-2 was used as a cell, and the test sample shown in 3-3 was used instead of the test sample shown in 1-3 as a test sample. 1 was performed in the same manner as the growth inhibition test shown in 1-4 of 1-4.
[0035]
3-5. result
The cell growth inhibitory effect of rice shochu distiller freeze-dried substance on various tumor cells was examined. The results are shown in FIG.
[0036]
[Table 3]
Figure 0004455779
[0037]
As is clear from FIG. 10, a remarkable cell growth inhibitory effect of 90% or more was observed on human gastric cancer cells and human lung adenocarcinoma cells.
From these results, it was suggested that shochu distilled spirits such as shochu distilled spirits and wheat shochu distilled spirits have a therapeutic and preventive effect on cancer.
[0038]
Reference example
<Single-dose toxicity test for shochu-distilled normal rats>
To confirm the safety of shochu distilled spirit used in the present invention as food and pharmaceuticals, a toxicity test was performed using normal rats. Indicates.
(Test specimen preparation)
The potato shochu distilled spirit freeze-dried substance was dissolved in 29 times the amount of PBS (-), and the barley shochu distilled spirit freeze-dried substance was dissolved in the 6.5-fold amount of PBS (-) (corresponding to the stock solution concentration). Concentrations are 34.5 mg / ml for shochu shochu-distilled lyophilized substance and 150 mg / ml for wheat shochu-distilled lyophilized substance. After dissolution, a filter sterilized with a 0.45 μm filter was used.
[0039]
(Test method)
Animal experiments were conducted at the facility of Kudo Co., Ltd.
Normal rats were randomly divided into 4 groups per group, and a single-dose toxicity test of shochu distilled spirit was performed. The administration method was oral administration and intravenous injection. The dose was 15 ml / kg, and the entire amount was administered from the oral and tail veins in about 3 minutes. During the experimental period, general condition observation and body weight measurement were performed every day after the start of administration. Six days after administration, all the cases were fasted for about 19 hours, then incised under ether anesthesia, blood was collected from the abdominal vena cava, and the collected blood was left at room temperature for about 60 minutes, and then at 3000 rpm. Centrifugation for 15 minutes and using the obtained serum, albumin, ALP activity, urea nitrogen, creatinine, glucose, GOT / AST activity, GPT / ALT activity, total bilirubic acid, total cholesterol, neutral fat, total protein were measured.
After collecting blood from all animals, the animals were dissected and macroscopic observations of various organs were performed. After necropsy, the liver, thymus, heart, kidney, lung, and spleen were removed, organ weights were measured, and body weight-specific organ weights were calculated based on the body weight of the day.
[0040]
In addition, the representative instruments used in this experiment are described below for reference.
1. Biochemical automatic analyzer Fuji Dry Chem 3500V (trade name, manufactured by Fuji Film Co., Ltd.)
Nicopet Ex (1000μ) (Brand name, Nitilyo)
Fuji Dry Chem Clean Chip (trade name, manufactured by Fuji Film Co., Ltd.)
Fuji Dry Chem Slide ALB-P (trade name, manufactured by Fuji Film Co., Ltd.)
Fuji Dry Chem Slide ALP-P (trade name, manufactured by Fuji Film Co., Ltd.)
Fuji Dry Chem Slide BUN-P (trade name, manufactured by Fuji Film Co., Ltd.)
Fuji Dry Chem Slide CRE-P (trade name, manufactured by Fuji Film Co., Ltd.)
Fuji Dry Chem Slide GLU-P (trade name, manufactured by Fuji Film Co., Ltd.)
Fuji Dry Chem Slide GOT / AST-P (trade name, manufactured by Fuji Film Co., Ltd.)
Fuji Dry Chem Slide GPT / ALT-P (trade name, manufactured by Fuji Film Co., Ltd.)
Fuji Dry Chem Slide TBIL-P (trade name, manufactured by Fuji Film Co., Ltd.)
Fuji Dry Chem Slide TCHO-P (trade name, manufactured by Fuji Film Co., Ltd.)
Fuji Dry Chem Slide TG-P (trade name, manufactured by Fuji Film Co., Ltd.)
14 Fuji Dry Chem Slide TP-P (trade name, manufactured by Fuji Film Co., Ltd.)
[0041]
(result)
A single-dose toxicity study of shochu-distilled lyophilized substance in normal rats was investigated. The sample concentration was set to a stock solution equivalent concentration. As a result of observing the general state of the rats for one week immediately after administration, no abnormal symptoms or deaths were observed in any of the administration groups. From the body weight measurement (FIG. 11), the control group, the sample administration group, There was no significant difference between the two. Moreover, no abnormal findings were observed in all organs from macroscopic observation after dissection. In addition, after autopsy, the heart, thymus, kidney, liver, spleen, and lungs were removed, organ weights were measured, and the body weight-specific organ weight (organ weight per 100 g of rat body weight) was calculated based on the body weight of the day. The results are shown in FIGS. As is clear from the figure, no significant difference in body weight specific organ weight was observed between the control group and the administration group. It should be noted here that the effect of administration is seen on the kidney, which is said to be the most frequently damaged organ because it is the first target organ when administered intravenously, and the liver that is susceptible to drug injury when administered orally. It was not.
Next, a biochemical test was performed using serum obtained by centrifuging the collected blood. The results are shown in FIGS. As is clear from the figure, there was no significant difference between the control group and the sample administration group in all the test items.
[0042]
From the above results, it was clarified that wheat and shochu distilled spirits do not show acute adverse effects and lethal toxicity to (1) normal rats. {Circle around (2)} It became clear that no toxicity to specific organs was shown. (3) It was revealed that there was no abnormality in biochemical examination. Therefore, it was suggested that the shochu distilled spirit of the present invention can be used safely as a pharmaceutical composition and a health food.
[Brief description of the drawings]
FIG. 1 is a diagram showing a manufacturing process of shochu.
FIG. 2 shows an infrared absorption spectrum of a lyophilized substance of a supernatant liquid of a shochu shochu distilled spirit.
FIG. 3 shows an ultraviolet absorption spectrum of a supernatant liquid of a shochu shochu distilled spirit.
FIG. 4 is a diagram showing the growth inhibitory effect of potato shochu distilled spirits on various tumor cells.
FIG. 5 shows an infrared absorption spectrum of a lyophilized substance of a supernatant of wheat shochu distilled spirit.
FIG. 6 shows an ultraviolet absorption spectrum of a supernatant of wheat shochu distilled spirit.
FIG. 7 is a graph showing the growth inhibitory effect of barley shochu distillers on various tumor cells.
FIG. 8 shows an infrared absorption spectrum of a freeze-dried substance of a supernatant of rice shochu distilled spirit.
FIG. 9 shows an ultraviolet absorption spectrum of a supernatant of rice shochu distilled spirit.
FIG. 10 is a graph showing the growth inhibitory effect of rice shochu distilled spirits on various tumor cells.
FIG. 11 is a graph showing changes in weight of rats.
FIG. 12 is a view showing the weight of each organ of the rat after oral administration.
FIG. 13 is a graph showing the weight of each organ of the rat after intravenous administration.
FIG. 14 is a view showing results of blood biochemical examinations of orally administered rats.
FIG. 15 is a diagram showing results of blood biochemical examinations of orally administered rats.
FIG. 16 is a diagram showing results of blood biochemical examinations of intravenously administered rats.
FIG. 17 is a diagram showing results of blood biochemical examination of intravenously administered rats.

Claims (7)

焼酎蒸留粕の遠心分離上澄み液又は該遠心分離上澄み液の凍結乾燥物を有効成分として含有することを特徴とする、胃癌、悪性黒色腫、肺腺がん及び肝臓がんから選ばれる腫瘍の予防又は治療用医薬組成物。  Prevention of tumor selected from gastric cancer, malignant melanoma, lung adenocarcinoma and liver cancer, comprising as an active ingredient a centrifugal supernatant of shochu distilled spirit or a freeze-dried product of the centrifugal supernatant Or a therapeutic pharmaceutical composition. 焼酎蒸留粕が芋焼酎の蒸留粕である請求項1記載の医薬組成物。  The pharmaceutical composition according to claim 1, wherein the shochu distilled spirit is a shochu distilled spirit. 焼酎蒸留粕が米焼酎の蒸留粕である請求項1記載の医薬組成物。  The pharmaceutical composition according to claim 1, wherein the shochu distilled spirit is a rice shochu distilled spirit. 腫瘍が胃癌である請求項1〜3のいずれか1項記載の医薬組成物。  The pharmaceutical composition according to any one of claims 1 to 3, wherein the tumor is gastric cancer. 腫瘍が悪性黒色腫である請求項1又は2記載の医薬組成物。  The pharmaceutical composition according to claim 1 or 2, wherein the tumor is malignant melanoma. 腫瘍が肺腺がんである請求項1〜3のいずれか1項記載の医薬組成物。  The pharmaceutical composition according to any one of claims 1 to 3, wherein the tumor is lung cancer. 腫瘍が肝臓がんである請求項1〜3のいずれか1項記載の医薬組成物。  The pharmaceutical composition according to any one of claims 1 to 3, wherein the tumor is liver cancer.
JP2001115081A 2001-04-13 2001-04-13 Pharmaceutical composition for tumor treatment and health food Expired - Fee Related JP4455779B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001115081A JP4455779B2 (en) 2001-04-13 2001-04-13 Pharmaceutical composition for tumor treatment and health food

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001115081A JP4455779B2 (en) 2001-04-13 2001-04-13 Pharmaceutical composition for tumor treatment and health food

Publications (2)

Publication Number Publication Date
JP2002308793A JP2002308793A (en) 2002-10-23
JP4455779B2 true JP4455779B2 (en) 2010-04-21

Family

ID=18966039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001115081A Expired - Fee Related JP4455779B2 (en) 2001-04-13 2001-04-13 Pharmaceutical composition for tumor treatment and health food

Country Status (1)

Country Link
JP (1) JP4455779B2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4694099B2 (en) * 2003-02-10 2011-06-01 三和酒類株式会社 Antioxidants related to in vivo oxidation
JP2004352681A (en) * 2003-05-30 2004-12-16 Denen Shuzo Kk Agent for suppressing cancer cell growth and method for producing the same
JP2006199618A (en) * 2005-01-20 2006-08-03 Ryuichi Kamioka Bleaching agent and tyrosinase inhibitor containing residue of extraction of shochu (distilled spirit) lee or extract of shochu lee
JP4576487B2 (en) * 2006-03-09 2010-11-10 霧島酒造株式会社 Breads using sweet potato shochu distilled liquor and method for producing the same
JP4684965B2 (en) * 2006-07-24 2011-05-18 ヤヱガキ醗酵技研株式会社 Functional food and production method
JP5549008B2 (en) * 2009-10-27 2014-07-16 国立大学法人 鹿児島大学 Anti-allergic agent or anti-atopic inflammatory agent containing potato shochu or a substance derived therefrom
JP5804391B2 (en) * 2012-03-08 2015-11-04 株式会社アップウェル Anti-glycation agent
JP6651201B2 (en) * 2018-01-30 2020-02-19 学校法人金沢工業大学 Method for producing resistant protein-containing material

Also Published As

Publication number Publication date
JP2002308793A (en) 2002-10-23

Similar Documents

Publication Publication Date Title
KR20030069991A (en) Homeostasis-maintaining agents
JP2008174539A (en) Healthy and functional food for obesity patient using purple-colored potato
RU2557408C2 (en) Unpurified caffeine complex, improved food products with usage of unpurified caffeine complex and such products application methods
KR20200002260A (en) Composition for preventing and treating of obesity or metabolic disease comprising Elaeagnus umbellata extracts
JP4455779B2 (en) Pharmaceutical composition for tumor treatment and health food
JPWO2004100969A1 (en) Therapeutic agent
JP2007519715A (en) A composition comprising a kabonashi extract, a dangwei extract, or a mixed herbal extract thereof as an active ingredient
JP5064652B2 (en) Diabetes prevention and treatment composition and health food containing active ingredients thereof
JPWO2004112817A1 (en) Celery family-derived extract and method for producing the same
JP2006056836A (en) Adipose tissue-specific secreted protein production-enhancing composition
WO2006082743A1 (en) Therapeutic agent
JP2006199618A (en) Bleaching agent and tyrosinase inhibitor containing residue of extraction of shochu (distilled spirit) lee or extract of shochu lee
JP5508656B2 (en) Final glycation product formation inhibiting composition
JP4071062B2 (en) Ethanol extraction residue from shochu distilled spirit, ethanol extract and production method thereof
JP5044643B2 (en) Serum uric acid level-lowering agent and food / beverage products with a label to reduce serum uric acid level
US9737583B2 (en) Composition for prevention or treatment of acute renal failure including herbal extract or fraction thereof as active ingredient
KR20160026595A (en) Composition for preventing or improving obesity and obesity-related disease comprising mixture of Coix lacryma-jobi L. var., Lentinus edodes, Poncirus trifoliata Rafin and Corn silk
JP2008031076A (en) Adiponectin production enhancer
KR101344564B1 (en) Composition comprising extract of hot peppers and Chinese peppers for preventing or treating of obesity or hyperlipidemia
JP2013177330A (en) Anti-inflammatory agent including lees of sweet potato distilled spirit or its treated material
KR20180075763A (en) Composition comprising the ethanol extract of Portulacea oleracea for preventing and treating of Alcoholic liver damage
JP2021136983A (en) Nitric oxide production promoter and use thereof
JP4873605B2 (en) A composition having an angiogenesis-inhibiting action comprising a cereal-derived ingredient as an active ingredient
JP2020019756A (en) Nitric oxide production promoter
WO2022138258A1 (en) Pde5 inhibitor

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080526

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091029

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091211

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100107

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100204

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130212

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4455779

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140212

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees